Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan’s Chugai Pharmaceutical denies Roche takeover reports
In a statement, the Japanese firm said that the media reports regarding Roche’s intention to own 100% of Chugai shares is not based on any announcement made by
In a statement, the Japanese firm said that the media reports regarding Roche’s intention to own 100% of Chugai shares is not based on any announcement made by
In March 2014, Pragma acquired Moxatag from Shionogi and has been working to make the product available in time for the upcoming cold and flu season. Pragma spokesperson
Currently, AG-221 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies. Agios chief medical officer Dr Chris Bowden said the company believes
The company said that Plegridy is the only pegylated beta interferon approved to use in RMS, which is dosed once every two weeks. The drug can be administered
With this approval in advanced cervical cancer, Avastin is approved in the US for the treatment of five distinct tumor types. The FDA approval is based on the
The company develops new therapies intended to improve outcomes in patients suffering from life-threatening diseases. La Jolla Research and Development vice-president and an inventor on the allowed patent
According to the company, the two patents (patent numbers are 8,771,732 and 8,765,175) will be Orange Book-listable. The two patents complement two additional issued formulation patents, as well
As part of the deal, Ligand will be receiving an up-front payment and is also eligible to get revenue from Captisol material sales, potential milestone payments and royalties
The US FDA has also granted priority review status for the BLA with an expected Prescription Drug User Fee Act (PDUFA) action date of 14 February 2015. Pfizer
The Phase III program will assess the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled